This review focuses on nicotine comorbidity in schizophrenia, and the insight into this
problem provided by rodent models of schizophrenia. A particular focus is on age …

It is now well established that many of society's most devastating and costly neurological
diseases and disorders arise from trauma at, or shortly after birth. In some cases deficits are …

Repeated daily treatments of perinatal rats with the dopamine D 2-receptor (D 2-R) agonist
quinpirole for a week or more produces the phenomenon of 'priming'—gradual but long-term …

Ontogenetic treatment of rats with the dopamine D2‐like receptor agonist quinpirole
produces a significant increase in dopamine D2 receptor sensitivity that persists throughout …

Abstract Male and female Sprague–Dawley rats were administered quinpirole (1 mg/kg, ip)
or saline once daily from postnatal day (P) 1 to P21. This drug treatment has been shown to …

This study was designed to analyze the effects of nicotine on yawning behavior and
neurotrophin content in the hippocampus and frontal cortex of D2‐receptor primed female …

Developmental exposure to the dopamine D2/3 receptor agonist quinpirole is reported to
induce D2 priming, impair Morris water maze performance, reduce acoustic startle prepulse …

Over the past 60 years, a large number of selective neurotoxins were discovered and
developed, making it possible to animal-model a broad range of human neuropsychiatric …

Rationale Increases in dopamine D 2-like receptor function are common in several
psychological disorders that demonstrate a four to five fold increase in nicotine abuse …

Neonatal quinpirole (dopamine D2/D3 agonist) treatment to rats has been shown to
increase dopamine D2 receptor sensitivity throughout the animal's lifetime. Male and female …